

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

POSITIVE PROFIT ALERT

This announcement is made by Common Splendor International Health Industry Group Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Group is expected to record an increase of not less than 100% in profit for the six months ended 30 June 2018 (the “**Interim Period**”) as compared to that of the corresponding period in 2017 of approximately HK\$5.5 million. The expected increase in profit for the Interim Period is mainly attributable to (i) an increase in revenue and gross profit of the medical anti-aging business for the Interim Period; (ii) a fair value gain on derivative financial liabilities arising from the redemption of a convertible bond during the Interim Period; and (iii) a decrease in income tax expense for the Interim Period. The expected increase in profit for the Interim Period is partially offset by the Group’s expected decrease in other income, increase in administrative expenses, decrease in share of results of associates and increase in finance cost, for the Interim Period.

As the Company is still in the process of preparing its unaudited condensed consolidated results for the Interim Period, the information contained in this announcement is only based on the preliminary assessment by the Board based on the unaudited condensed consolidated management accounts of the Group for the Interim Period and the information currently available to the Company, of which financial figures or information have not been reviewed by the audit committee of the Board or reviewed or audited by the external auditors of the Company. The results announcement of the Group for the Interim Period is expected to be published by the Company on 30 August 2018.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 15 August 2018

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors; and Mr. Mai Yang Guang, Mr. Wong Yiu Kit, Ernest and Mr. Lam Chi Wing as independent non-executive Directors.